On February 5, 2021 Ipsen (Euronext: IPN; ADR: IPSEY) reported that new data from its growing oncology portfolio will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers Symposium (ASCO GU), taking place virtually from 11-13 February 2021 (Press release, Ipsen, FEB 5, 2021, View Source [SID1234574671]).11 A total of 10 abstracts spanning several genitourinary cancers including advanced RCC, and metastatic, castration-resistant prostate cancer (mCRPC), highlight the utility of Ipsen’s medicines and its commitment to advancing patient care.1-10
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The presentations showcased at ASCO (Free ASCO Whitepaper) GU exemplify Ipsen’s commitment to prioritize outcome measures which directly impact patients’ lives," said Amauri Soares, Vice President, Medical Affairs Oncology, Ipsen. "New data from the Phase III CheckMate -9ER trial highlight how first-line treatment with the combination of cabozantinib and nivolumab has the potential to extend the lives of patients living with advanced RCC without having to compromise on quality of life compared with sunitinib. We’re looking forward to sharing these data with the medical community at ASCO (Free ASCO Whitepaper) GU and bringing this important treatment option to patients at the earliest opportunity."
Highlights from key data on Ipsen medicines to be presented during the ASCO (Free ASCO Whitepaper) GU 2021 Symposium include:
Extended follow-up outcomes data from the CheckMate -9ER study including patients living with advanced RCC and sarcomatoid features (sRCC) – an aggressive histologic subtype associated with poor prognoses1
Patient reported outcomes of patients living with advanced RCC – additional analysis from the CheckMate -9ER study of the combination of Cabometyx (cabozantinib) with Opdivo (nivolumab) versus sunitinib2
A comparative, retrospective real-world evidence study suggesting Cabometyx (cabozantinib) was associated with a significantly higher response rate versus other TKIs (axitinib, lenvatinib, pazopanib, sorafenib, sunitinib) in patients living with metastatic renal cell carcinoma (mRCC) following checkpoint inhibitor (CPI) treatment3
Findings from a study using machine learning to explore the potential synergistic effects of Cabometyx (cabozantinib) and a programmed cell death protein 1 (PD1) inhibitor in mRCC4
Trial design of the Phase III randomized, open-label CONTACT-02 study of Cabometyx (cabozantinib) plus Tecentriq (atezolizumab) versus second novel hormone therapy (NHT) in patients living with mCRPC5